A U.S. appeals court said Tuesday that an Oregon law meant to increase transparency for prescription drug prices is constitutional, turning away a challenge brought by a pharmaceutical industry group.

Johnson & Johnson asked the board to remove Trifia from the affordability review, saying the drug did not meet the board’s prioritization metrics and urging additional time to analyze draft reports; staff explained the selection process and carrier reporting criteria used to build preliminary lists.

At a Cabinet meeting the president announced what he called a most-favored-nation policy and said drugmakers agreed to prices that will cut many U.S. prescription costs; the Health official present said 16 of 17 companies have reached agreements and rural health funding will support access.

Dr. Andy York told the Finance Committee on Jan. 15 that the board has completed preliminary affordability determinations for two diabetes drugs and has recommended policy options — including an incentive to curb list‑price growth and plans to pursue upper payment limits — with final actions expected after public methodology review this spring.

On a Tennessee visit, HHS Secretary Robert F. Kennedy Jr. outlined federal steps he said will lower drug prices, expand rural health funding and use AI to detect Medicare/Medicaid fraud; he also previewed an April report on baby‑formula contaminants and urged diet-based prevention strategies for child health.